Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | DDX3X | O00571 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12525964 | 0.88 | CSNK2A2 (0.72) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17318586 | 0.88 | KDM4E (0.66) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17318553 | 0.87 | NPC1 (0.61) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL26884000 | 0.80 | RAB9A (0.62) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL11386627 | 0.78 | KMT2A (0.67) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17318645 | 0.77 | SMN1; SMN2 (0.76) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12700360 | 0.77 | DDX3X (0.84) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17318640 | 0.77 | RXFP1 (0.58) | NPC1RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL17318655 | 0.77 | NPC1 (0.84) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL22616866 | 0.77 | USP2 (0.67) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | disclosed |
| WO-2015187827-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, EIF2AK2 | NPC1 237/4885RAB9A 1296/4885ALDH1A1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.